Key result
CAR-T therapy is linked to life-threatening cytokine release syndrome and severe cardiovascular complications.
Why the study?
What are the cardiovascular complications associated with CAR T-cell therapy and how should they be managed?
Population
Patients with relapsed and refractory hematologic malignancies and other malignancies receiving CAR T-cell…
Design
Review
Authors
Loading...
CAR T-cell therapy can cause severe cardiovascular complications secondary to cytokine release syndrome, highlighting the need for baseline cardiovascular risk stratification and multidisciplinary management.
What are the cardiovascular complications associated with CAR T-cell therapy and how should they be managed?
CAR T-cell therapy can cause severe cardiovascular complications secondary to cytokine release syndrome, highlighting the need for baseline cardiovascular risk stratification and multidisciplinary management.
Ganatra et al. (2019) conducted a review in Hematologic malignancies and cytokine release syndrome. Chimeric antigen receptor (CAR) T-cell therapy was evaluated. Chimeric antigen receptor (CAR) T-cell therapy is associated with potentially life-threatening cytokine release syndrome and cardiovascular complications, necessitating careful cardiac evaluation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: